Law enforcement agents monitor insulin, delay to delay the next adjustment

Law enforcement agents monitor insulin, delay to delay the next adjustment


Two parliamentarians reported on Thursday to deal with insulin prices, providing appropriate samples for the implementation of the bill on drug prices next year.

Suggestions from Reps Tom Reed (R-N.Y.) With Diana DeGette (D-Colo.), The Crisis Crisis Crisis leader, will be shocked by the use of funds. Protesters called on the council to limit the protection of anti-insulin to prevent new molecules from entering the market.

"Experts expect that insulin can kill 20 to 40 percent more than their own names, providing health care for patients," the report said.

Terms can prevent drug users and pharmaceuticals (PBMs) from compensating rates with distribution divisions, according to the report. These include the possibility of contracting a deal between vendors and PBMs who have entered Medicare, Medicaid or individuals and working markets; the requirements of PBMs and health plans to show the amount of income they received and exceeded with what they value; and a combination of reasonably comfortable prices that are discussed in the list of products rather than the list of prices.

The study also recommended that the council encourage biotech producers to produce insulin insulin by preventing the "retirement" operation which is used as a drug-maker.

The facts included in the reports report the 2017 Republican Republican government signed by Brian Sandoval, which will force professionals to show how they make their prices for insulin. It is also best for the law on insulin prices to date.

About 7.5 million diabetes require insulin, while prices continue. Between 2002 and 2013 price prices are based on the US Drug Association. The cost paid to the patients costs about $ 40 per annum to $ 130.